Wolters Kluwer Health Completes Divestment of ProVation

Wolters Kluwer Health Completes Divestment of ProVation

March 9, 2018 - Wolters Kluwer Health announces today that it has completed the divestment of ProVation Medical to Clearlake Capital Group, L.P., as originally announced on January 11, 2018.

About Wolters KluwerWolters Kluwer N.V. (AEX: WKL) is a global leader in information, software solutions, and services for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer reported 2017 annual revenues of €4.4 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries, and employs 19,000 people worldwide.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information about our solutions and organization, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.

MediaAnnemarije Dérogée-Pikaar Global Brand & Communications t + 31 172 641 470[email protected] Investors/AnalystsMeg GeldensInvestor Relationst + 31 172 641 407[email protected]

Ann JoyalGlobal Brand & Communications, Health781-392-3831[email protected]

Forward-looking StatementsThis report contains forward-looking statements. These statements may be identified by words such as "expect", "should", "could", "shall" and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains information which is to be made publicly available under Regulation (EU) 596/2014.

Attachment:

http://www.globenewswire.com/NewsRoom/AttachmentNg/971c65a3-e3bf-4318-8fbd-e5a8d1e4c466

Source: Wolters Kluwer NV

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA clears Merck's Keytruda combo for muscle-invasive bladder cancer
• Wolters Kluwer launches Genya Magazzino to help Italian SMEs streamline inventory control and improve decision‑making
• XRP Price Prediction: Pepeto Presale Targets What XRP’s Ceiling Cannot Deliver